Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.
about
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemopreventionChemotherapy and chemoprevention by thiazolidinedionesFunctions of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Gynecologic DisordersAdditive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARsFatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer.The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination.Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension.Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF.15-Deoxy-Δ(12,14)-prostaglandin J2 Induces Apoptosis and Upregulates SOCS3 in Human Thyroid Cancer Cells.Valproic acid sensitizes TRAIL-resistant anaplastic thyroid carcinoma cells to apoptotic cell death.Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells.Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas tumor transcriptome profile.
P2860
Q24601222-6B9C6ACC-BA54-4476-B873-76A7B25A7244Q27011352-2736DC45-2232-4C61-8010-8765FA70B040Q28082264-724A0022-CB33-4ED4-8565-1CE281CBD11DQ28550672-944A19B6-07E4-4EF6-9B89-269233ACC594Q35857189-A40B6C3C-8BCA-4EB1-9555-D39A03FDC27AQ36090448-11A250BF-A17B-4858-9180-F0D707746BBAQ36340848-7D86D765-1DEC-4B84-8AAB-A91799B0F5D2Q39464321-C55B5C30-B562-49EF-B252-3C8E7A518283Q40845153-90A05676-F998-4EE9-A2DF-E0F9219D6B7FQ44109526-B55B44B7-342C-4EB4-BE08-E2C122B0B741Q47129762-3AB497FB-91F1-4676-AE11-F1F5E5BD4B36Q49220207-5E089AE0-1AF4-43C6-8520-BC34D9B5C083
P2860
Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Combined treatment with TRAIL ...... of ovarian cancer cell lines.
@en
Combined treatment with TRAIL ...... of ovarian cancer cell lines.
@nl
type
label
Combined treatment with TRAIL ...... of ovarian cancer cell lines.
@en
Combined treatment with TRAIL ...... of ovarian cancer cell lines.
@nl
prefLabel
Combined treatment with TRAIL ...... of ovarian cancer cell lines.
@en
Combined treatment with TRAIL ...... of ovarian cancer cell lines.
@nl
P2093
P2860
P50
P1476
Combined treatment with TRAIL ...... of ovarian cancer cell lines.
@en
P2093
Dirk O Bauerschlag
Julia Biernath-Wüpping
Karen Bräutigam
Nicolai Maass
P2860
P2888
P304
P356
10.1007/S00432-010-0952-2
P577
2010-09-29T00:00:00Z